ABC
L’acne volgare
FILIPPO LONGO1, FRANCO PANIZON2
1Dermatologo, IRCCS “Burlo Garofolo”, Trieste;
2Professore Emerito, Dipartimento di Scienze della Riproduzione e dello Sviluppo, Università di Trieste
Ottobre 2005 - pagg. 541 -543
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. Darmstadt GL, Salbury R. Acne. In: Nelson
Textbook of Pediatrics, ed 17, 2004:2242.
2. Brown S, Shalita A. Acne vulgaris. Lancet 1998;351:1871.
3. Webster GF. Acne vulgaris. BMJ 2002; 325:475.
4. Bergfeld WF. The pathophysiology of acne vulgaris in children and adolescents. Cutis 2004;74(3):189-92.
5. Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999;140:672.
6. Koo J. The psychosocial impact of acne. Patients perceptions. J Am Acad Dermatol 1995; 32:525.
7. Cunliffe WJ. Acne and unemployment. Dr J Dermatol 1986;115:386.
8. Thiboutot D, Knaggs H, Gilliand K, et al. Activity of 5-alfa-reductase and 17-beta-hydroxi steroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. Dermatology 1998;196:38.
9. Lucky AW, Biro FM, Simbart LA, et al. Prediction of severity of acne vulgaris in young adolescent girls. Result of five year longitudinal study. J Pediatr 1997;130:30.
10. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003;49:S1-37.
11. James WD. Acne. N Engl J Med 2005; 352:1463.
12. Vega B, Jonarrd A, Michel S. Regulation of toll-like receptor. 2 expression by adapalene. J Europ Acad Dermatol Venereol 2002; 16:23.
13. Shaw JC, White LE. Long term safety of spironolactone in acne. Results of an 8-years study. J Cutan Med Surg 2002;6:541.
14. Phillips TJ. An update on the safety and efficacy of topical retinoids. Cutis 2005; 75(suppl.2):14-22.
15. Hull PR, D’Arcy C. Isotretinoin use and subsequent depression and suicide: presenting the evidence. Am J Clin Dermatol 2003; 4:493.
16. Arowojolu AO, Gallo MF, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2004;(3):CD004425.
2. Brown S, Shalita A. Acne vulgaris. Lancet 1998;351:1871.
3. Webster GF. Acne vulgaris. BMJ 2002; 325:475.
4. Bergfeld WF. The pathophysiology of acne vulgaris in children and adolescents. Cutis 2004;74(3):189-92.
5. Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999;140:672.
6. Koo J. The psychosocial impact of acne. Patients perceptions. J Am Acad Dermatol 1995; 32:525.
7. Cunliffe WJ. Acne and unemployment. Dr J Dermatol 1986;115:386.
8. Thiboutot D, Knaggs H, Gilliand K, et al. Activity of 5-alfa-reductase and 17-beta-hydroxi steroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. Dermatology 1998;196:38.
9. Lucky AW, Biro FM, Simbart LA, et al. Prediction of severity of acne vulgaris in young adolescent girls. Result of five year longitudinal study. J Pediatr 1997;130:30.
10. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003;49:S1-37.
11. James WD. Acne. N Engl J Med 2005; 352:1463.
12. Vega B, Jonarrd A, Michel S. Regulation of toll-like receptor. 2 expression by adapalene. J Europ Acad Dermatol Venereol 2002; 16:23.
13. Shaw JC, White LE. Long term safety of spironolactone in acne. Results of an 8-years study. J Cutan Med Surg 2002;6:541.
14. Phillips TJ. An update on the safety and efficacy of topical retinoids. Cutis 2005; 75(suppl.2):14-22.
15. Hull PR, D’Arcy C. Isotretinoin use and subsequent depression and suicide: presenting the evidence. Am J Clin Dermatol 2003; 4:493.
16. Arowojolu AO, Gallo MF, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2004;(3):CD004425.